BOSTON–(Organization WIRE)–Bain Funds Specialty Finance, Inc. (NYSE: BCSF, the “Company”) right now announced it will report its economic benefits for the next quarter ended June 30, 2022 on Wednesday, August 3, 2022 right after market place near. Management will host a conference connect with on Thursday, August 4, 2022 at 8:30 a.m. Jap Time to discuss the Company’s economic success.
Convention Contact Details:
A meeting phone to explore the Company’s financial success will be held stay at 8:30 a.m. Japanese Time on August 4, 2022. Remember to stop by BCSF’s webcast website link positioned on the Gatherings & Shows web site of the Trader Sources segment of BCSF’s web site at http://www.baincapitalbdc.com for a slide presentation that enhances the Earnings Convention Contact.
Participants are also invited to obtain the conference phone by dialing one particular of the adhering to numbers:
Domestic: 1-800-289-0571
International: 1-323-794-2093
Convention ID: 9543241
All members will need to have to reference “Bain Cash Specialty Finance – Second Quarter Ended June 30, 2022 Earnings Conference Call” when linked with the operator. All contributors are requested to dial in 10-15 minutes prior to the contact.
Replay Facts:
An archived replay will be out there approximately a few several hours after the convention phone concludes by August 11, 2022 by means of a webcast hyperlink found on the Investor Means part of BCSF’s web site, and by using the dial-in figures mentioned under:
Domestic: 1-844-512-2921
International: 1-412-317-6671
Convention ID: 9543241#
About Bain Cash Specialty Finance, Inc.
Bain Capital Specialty Finance, Inc. is an externally managed specialty finance business centered on lending to middle-current market organizations. BCSF is managed by BCSF Advisors, L.P., an SEC-registered expenditure adviser and a subsidiary of Bain Funds Credit, L.P. Considering that commencing financial investment operations on Oct 13, 2016, and by March 31, 2022, BCSF has invested somewhere around $5.3 billion in aggregate principal amount of credit card debt and fairness investments prior to any subsequent exits or repayments. BCSF’s investment decision aim is to create present-day cash flow and, to a lesser extent, money appreciation by direct originations of secured financial debt, including very first lien, to start with lien/very last out, unitranche and next lien financial debt, investments in strategic joint ventures, fairness investments and, to a lesser extent, corporate bonds. BCSF has elected to be regulated as a small business development corporation beneath the Expenditure Corporation Act of 1940, as amended.
Ahead-On the lookout Statements
Selected facts contained herein could comprise “forward-on the lookout statements” within just the which means of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical specifics provided herein may perhaps represent ahead-on the lookout statements and are not guarantees of upcoming effectiveness or outcomes and contain a amount of threats and uncertainties. True final results may well differ materially from these in the ahead-looking statements as a consequence of a number of components, such as these explained from time to time in filings with the U.S. Securities and Trade Commission. The Business undertakes no obligation to update any forward-wanting statement made herein. All forward-seeking statements talk only as of the day of this press release.
Working margins at hospitals and health methods have been strike really hard by the pandemic, and the Omicron surge was an added setback as the healthcare sector ongoing to struggle at the commencing of the yr.
The effects of the Omicron variant has been palpable, as median running margins remained in the crimson for a next straight thirty day period in February, and most organizations saw declines in margins, revenues and inpatient volumes, in accordance to the most recent Kaufman Hall Flash report.
The median Kaufman Hall Operating Margin Index reflecting real margins for the month was -3.45{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, up from -4.52{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} in January but even now perfectly under sustainable concentrations. Restoration from the Omicron surge is probable to be gradual, and there could be added setbacks forward if other variants, these as the Omicron subvariant BA.2, direct to long term surges.
The improvement in median margin was pushed by disproportionate raises amid hospitals that saw margin gains in February when compared to hospitals that experienced margin declines. Even so, most U.S. hospitals claimed margin declines for the month.
The median modify in operating margin was down 11.8{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} from January to February, and the median change in Operating EBITDA Margin lowered 7.5{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} thirty day period-over-thirty day period.
12 months-over-year, the median alter in working margin was down 26.7{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} and the median change in functioning EBITDA margin declined 24.3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}. Median margin alterations were being the most spectacular in comparison to just right before the begin of the pandemic, with working margin down 42.4{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} and running EBITDA margin down 37.5{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} vs. February 2020.
What’s THE Influence
In conditions of volumes, outpatient volumes were being gradual to get well in February, even though inpatient volumes lowered with the fall in COVID-19 hospitalizations. Client days were down 13.3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} thirty day period-in excess of-thirty day period and 4.7{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} as opposed to February 2020. Modified client times decreased 7.6{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} from January to February and 4.7{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} vs. February 2020.
Fewer seriously unwell COVID-19 people also contributed to shorter medical center stays. Regular Length of Stay (LOS) dropped 5.3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} month-above-month, but rose 3.6{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} YOY and 12.6{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} vs. the exact same thirty day period in 2020.
Operation volumes observed moderate improves, as some people returned for nonurgent procedures that have been delayed during the Omicron surge.
Lousy volume functionality led to month-above-thirty day period income declines in February. Gross working income was down 7.4{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} and outpatient earnings dropped 5{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} from January ranges. Inpatient earnings experienced the major reduce, down 19.3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} adhering to a practically 3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} boost the prior month because of to January’s spike in COVID-related hospitalizations.
Clinic bills noticed advancements month-about-thirty day period as hospitals bought some aid following the powerful calls for of the Omicron surge. Total cost per adjusted discharge was down 4.5{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, Labor price for each adjusted discharge lowered 6.1{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, and non-labor expenditure for every altered discharge dropped 3.6{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} from January to February.
Common labor shortages and ongoing source chain problems continued to generate up calendar year-more than-calendar year modified charges. Whole price per modified discharge rose 10.4{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} as opposed to February 2021 and 30.7{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} vs. February 2020.
Labor cost for each altered discharge was up 15.3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} 12 months-around-12 months vs. 2021 and 32{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} compared to February 2020. Staffing degrees declined after once again, highlighting the affect of labor scarcity wage pressures in pushing up over-all labor expenses. Entire-Time Equivalents (FTEs) for every altered occupied mattress dropped 2.8{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} thirty day period-in excess of-thirty day period, 4.8{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} yr-above-year, and were being flat vs. February 2020.
Non-labor charges for each altered discharge rose 8{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} as opposed to February 2021 and 25.8{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} vs. February 2020. Drug cost per altered discharge experienced the largest maximize of any cost metric compared to pre-pandemic levels at 40.6{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}.
THE Greater Trend
Some of these tendencies were foreshadowed by a November 2021 report from Fitch Ratings demonstrating that labor shortages and supply chain issues are a rising menace to gain margins.
Various things are contributing to labor pressures, such as team burnouts prompted by the enduring COVID-19 pandemic and an overall scarcity of capable enable, which has resulted in larger prices to employ short term personnel, as properly as wage inflation.
Additionally, the report observed that deficiency of employees is forcing some in-patient behavioral health and senior housing operators to decreased admission costs.
Supply chain troubles are also incorporating strain to financial gain margins, predominantly due to higher transportation expenditures incurred by distributors. The professional medical device subsector is also becoming impacted by the international shortage of semiconductors wanted for their production procedures.
Twitter: @JELagasse E-mail the author: jeff.lagasse@himssmedia.com
Aon PLC noted elevated whole profits, organic and natural profits and gain for the fourth quarter of 2021, but the $1 billion dollar termination payment it paid in the third quarter associated to its unsuccessful bid to acquire Willis Towers Watson PLC dragged down earnings for the year.
In 2022, the brokerage expects to see fees rise as wages improve and travel and enjoyment prices increase two many years immediately after the starting of the COVID-19 pandemic, but it expects to see money added benefits if desire premiums rise.
Aon reported fourth-quarter earnings of $3.08 billion, a 3.9{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} improve more than the similar time period the prior 12 months. On an natural basis, which excludes the effect of mergers and acquisitions and foreign exchange fluctuations, income greater 10{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}.
Rival brokerages have also documented powerful natural and organic income growth for the fourth quarter as insurance prices ongoing to increase in 2021.
Income for Aon’s main coverage brokerage business enhanced 11{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $1.85 billion, up 12{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} on an natural basis reinsurance earnings rose 12.7{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $222 million, up 13{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} on an organic and natural foundation overall health consulting revenue fell 13. 3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $651 million but enhanced 7{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} on an organic and natural basis, reflecting the sale of its retiree health treatment exchange company and retirement and investment profits grew 1.9{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $364 million, up 1{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} on an organic and natural foundation.
Internet money greater 63.2{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $873 million as functioning fees fell and profits greater owing to the sale of the retiree health and fitness trade, which was initially agreed on as part of its unsuccessful hard work to buy rival Willis Towers Watson.
For the complete 12 months, Aon claimed earnings of $12.19 billion, up 10.2{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, and web cash flow of $1.31 billion, down 35.2{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}. Aon paid out a $1 billion termination cost in the third quarter related to the scuttled Willis deal, which fell apart in July due to antitrust fears.
On the lookout ahead, Aon expects to see an boost in shell out-associated expenditures this 12 months and will probably reward from mounting interest premiums, the brokerage’s major monetary executive reported on a conference connect with with analysts Friday.
Aon expects to broaden its earnings margin this yr “and as we seem to 2022 we also assume investments in colleagues, some ongoing resumption of (journey and entertainment expenses) and investments in extended-time period advancement,” mentioned Christa Davies, the brokerage’s main economic officer.
But Aon expects wage inflation to be offset by efficiencies, she claimed.
If curiosity prices rise, it will be “very positive” for Aon for the reason that its fiduciary financial investment income will rise by $60 million every time there is a 100 basis issue enhance in small-term desire charges and the company’s pension liabilities will be diminished, among other matters, Ms. Davies explained.
Inventory futures opened increased Thursday night as buyers took in earnings results from some key tech firms at the finish of a different risky 7 days.
Contracts on the S&P 500 received. Dow futures also highly developed,as part inventory Apple (AAPL) jumped in late investing after the Apple iphone-maker documented document quarterly revenue and superior-than-predicted profits inspite of supply chain issues. Meanwhile, Robinhood (HOOD) shares sank soon after the trading system missed on quarterly revenue, posted a much larger-than-expected quarterly drop in end users, and made available disappointing steering.
The S&P 500 was on monitor to put up a weekly decline of about 1.3{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, centered on Thursday’s closing selling prices. New reports showing a greater-than-expected rise in fourth-quarter U.S. GDP and enhancement in weekly jobless promises did very little to assistance switch shares all around throughout Thursday’s session. The Dow and Nasdaq have every also fallen more than the training course of the earlier week, with volatility climbing as traders regarded as the implications of the Federal Reserve’s much more hawkish monetary policy tilt for marketplaces.
“The markets digested this hawkish Fed pivot that I assume astonished folks in terms of its magnitude,” Scott Crowe, CenterSquare Financial investment Management chief financial investment strategist, informed Yahoo Finance Dwell on Thursday. “It wasn’t so extensive ago that they had been describing inflation as ‘transitory,’ but now they have their sights firmly established on moderating inflation. And I consider that is given the marketplace a good deal of indigestion as it begins to digest that rather dramatic change.”
Federal Reserve Chair Jerome Powell strongly signaled earlier this 7 days that a March liftoff on curiosity rates to earlier mentioned their existing close to-zero levels was in the cards. Even so, other issues remained — specifically all around just how immediately the Fed will raise fascination fees, and all over when and how rapidly the Fed will get started drawing down its approximately $9 trillion balance sheet and tightening money circumstances.
“All the things the Fed is accomplishing at this point we feel has just been priced in in excess of the final couple months. And that’s where by a great deal of the slide in the market place has appear from,” Morgan Stanley Controlling Director Kathy Entwistle told Yahoo Finance Stay on Thursday. “And the big query is, will we slide a minor little bit much more? What’s occurring?”
“We’re seeking at corporations and their earnings … to figure out whether or not or not we’re heading to have a very little little bit additional of a pullback in the sector or not,” she additional. “And that’s primarily based on what they can do heading forward, the place their possibilities are. And we’ve been listening to a ton about inflation. If you assume about a 7{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} inflation price, that’s really sizeable.”
“Back again in the slide, it was the retail trader that was keeping up the sector,” Entwistle explained. “And now, their sentiments have form of turned and they are no for a longer time optimistic about exactly where we are right now. So I consider we have to think about all of these things. We do imagine that the high quality, yet again, is going to do far better than growth.”
—
6:15 p.m. ET Thursday: Inventory futures bounce after Apple earnings
Here’s exactly where futures started investing Thursday night:
S&P 500 futures (ES=F): +30 points (+.69{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}), to 4,347.75
Dow futures (YM=F): +169 factors (+.5{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}), to 34,212.00
Nasdaq futures (NQ=F): +169 factors (+1.21{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}) to 14,155.75
Picture by: NDZ/STAR MAX/IPx 2022 1/24/22 People stroll previous the New York Inventory Trade (NYSE) on Wall Street on January 24, 2022 in New York.
ANN ARBOR, MI / ACCESSWIRE / November 12, 2021 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three and nine months ended September 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). Third quarter results do not include operations of PulseVet which were acquired on October 1, 2021.
Larry Heaton, Chief Executive Officer of Zomedica, stated that, “During the third quarter the team at Zomedica continued building the installed base of TRUFORMA® instruments through our Customer Appreciation Program (CAP), which provides select customers with an instrument at no charge as long as they agree to purchase assay cartridges. Customer response to this program has been encouraging, with 144 customers enrolled to date, and we plan to continue offering it through the end of the year. We expect revenue from these CAP program customers to build sequentially as they utilize cartridges currently available, and new ones as they are released to market. We continue to work with our partner, Qorvo Biotechnologies, to develop new assays for the TRUFORMA® instrument and expect to release several new assays to market in 2022.
Mr. Heaton continued, “Business development was an important focus of the Zomedica team during the third quarter, which led to the culmination of Zomedica’s first acquisition on October 1, 2021, when Pulse Veterinary Technologies (“PulseVet”) became a Zomedica Company. We’re excited about the opportunities to combine the sales and marketing efforts of the respective companies to broaden the introduction of PulseVet’s market-leading shock-wave therapy to the small animal market and the potential future opportunity to introduce TRUFORMA® technology into the equine market.”
“The third quarter reflected Zomedica’s dual approach to realizing growth – building the installed base of TRUFORMA® technology to produce organic growth, and active business development efforts through strategic investments to expand our product offerings, technologies and product development efforts. During the balance of the year, we’re continuing this strategy as we expand the sales and marketing teams and provide the training needed to effectively sell into the animal health marketplace.”
Summary Third Quarter 2021 Results
Zomedica recorded net loss and comprehensive loss for the three and nine months ended September 30, 2021 of approximately $6.3 million, or $0.01 per share, and approximately $15.1 million, or $0.05 per share, respectively, compared to a net loss and comprehensive loss of approximately $5.0 million, or $0.01 per share, and approximately $12.7 million, or $0.04 per share, for the three and nine months ended September 30, 2020.
Revenue for the three and nine months ended September 30, 2021 was $22,514 and $52,331, respectively, and resulted from the sale of our TRUFORMA® products and associated warranties. We commenced commercialization of TRUFORMA® on March 15, 2021 and accordingly have had only limited sales activity in the first three quarters of 2021.
Cost of revenue for the three and nine months ended September 30, 2021 was $17,899 and $59,433, respectively. As noted above, commercialization of TRUFORMA® commenced on March 15, 2021. We expect that cost of revenue will increase as we sell additional products in subsequent periods, inclusive of costs associated with PulseVet’s operations.
Research and development expense for the three and nine months ended September 30, 2021 was approximately $0.3 million and approximately $1.0 million, respectively, compared to approximately $2.7 million and $7.2 million for the three and nine months ended September 30, 2020, respectively, representing a decrease of approximately $2.4 million, or 89{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, over the prior three-month period and a decrease of approximately $6.2 million, or 86{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, for the prior nine-month period. The decrease in both periods was a result of an overall reduction in research and development costs related to TRUFORMA® as we completed development of the instrument and three of the first five assays and began transitioning to commercialization activities.
Selling, general and administrative expense for the three months ended September 30, 2021 was approximately $6.1 million, compared to approximately $2.3 million for the three months ended September 30, 2020, an increase of approximately $3.8 million, or 166{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}. The increase primarily was due to an increase in share-based compensation expense, which was approximately $1.5 million for the three months ended September 30, 2021, compared to approximately $0.2 million for the comparable period in 2020. Other significant increases include professional fees of approximately $2.1 million relating to the PulseVet acquisition and increased fees associated with SEC compliance requirements, and salaries for administrative and sales personnel of approximately $0.4 million.
Selling, general and administrative expense for the nine months ended September 30, 2021 was approximately $14.6 million, compared to approximately $5.4 million for the nine months ended September 30, 2020, an increase of approximately $9.2 million, or 169{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}. The increase primarily was due to an increase in share-based compensation expense, which was approximately $4.5 million for the nine months ended September 30, 2021, compared to approximately $0.5 million for the comparable period in 2020, as a result of stock option grants made during the first quarter of 2021. Other significant increases include professional fees of approximately $2.9 million, related primarily to the PulseVet acquisition, and the exchange of our Series 1 preferred stock, as well as increased fees associated with filings compliance requirements, salaries of approximately $1.1 million, regulatory fees incurred for the annual shareholders meeting of approximately $0.8 million largely as a result of administrative costs related to increases in the shareholder base, marketing, travel and office expense of approximately $0.3 million, and contracted expenditures of approximately $0.1 million.
Liquidity and Outstanding Share Capital
Zomedica had cash and cash equivalents of approximately $271.4 million as of September 30, 2021, compared to approximately $52 as of September 30, 2020. The increase in cash is mainly a result of the cash flows from financing activities, partially offset by cash flows used in operating and investing activities as discussed below. After giving effect to the acquisition of PulseVet, Zomedica had pro forma cash and cash equivalents of approximately $199.5 million as of September 30, 2021.As of September 30, 2021, Zomedica had shareholders’ equity of approximately $271.6 million.
Net cash used in operating activities for the nine months ended September 30, 2021 was approximately $9.4 million, compared to approximately $15.6 million for the nine months ended September 30, 2020, a decrease of approximately $4.2 million, or 40{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}. The reduction in net cash used in operating activities resulted primarily from a $4.5 million non-cash stock compensation expense in the 2021 period, approximately $0.5 million in gains recognized on extinguishment of debt, a loss on disposal of property of $0.2 million, and an increase in accounts payable in the 2021 period of approximately $3.2 million. These amounts were offset in part by an increase in inventory purchases of approximately $1.9 million. Other non-cash activity in the 2021 period included amortization and depreciation of approximately $0.3 million.
Net cash used in investing activities for the nine months ended September 30, 2021 was approximately $0.3 million, compared to net cash provided of approximately $1.0 million for the nine months ended September 30, 2020, an increase in net cash used of approximately $1.3 million, or 134{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}. The increase in net cash used in investing activities resulted from the receipt of cash from the modification of our lease in the first half of 2020, compared to investments of intangible and other property and equipment in the current period.
Net cash from financing activities for the nine months ended September 30, 2021 was approximately $219.1 million, compared to approximately $64.1 million for the nine months ended September 30, 2020, an increase of approximately $155.1 million, or 242{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}. The increase resulted primarily from the sale of our equity securities in 2021 for total gross proceeds of approximately $199.5 million, cash received of approximately $32.1 million from warrant exercises, and cash received of approximately $1.4 million from stock option exercises, offset by stock issuance costs of approximately $14.3 million.
As of September 30, 2021, Zomedica had an unlimited number of authorized common shares with 979,738,168 common shares issued and outstanding.
As of November 12, 2021, Zomedica had 979,894,668 common shares issued and outstanding.
For complete financial results, please see Zomedica’s filings on EDGAR and SEDAR or visit the Zomedica website at www.ZOMEDICA.com.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Reader Advisory
Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date
the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, our ability to successfully integrate and operate the PulseVet business, the sufficiency of our budgeted capital and operating expenditures, the cost, adequacy and availability of supplies required for our operations, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results, and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate and operate the Pulse Vet business, uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty regarding the cost, adequacy and availability of supplies required for our operations; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve
the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations: risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contacts PCG Advisory Group Kirin Smith, President ksmith@pcgadvisory.com +1.646.823.8656
Oct 15 (Reuters) – Goldman Sachs Team Inc (GS.N) on Friday reported a 66{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} surge in third-quarter income that smashed expectations, as Wall Street’s largest investment decision lender rode a report wave of M&A action and preliminary general public choices.
The lender posted profits of $5.28 billion up from $3.23 billion a calendar year in the past, capping a stellar quarter for Wall Street creditors, which have benefited from a rebounding U.S. overall economy, soaring fairness markets and a international deal-making bonanza.
Shares of Goldman Sachs have been up 2{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} in mid-morning trading.
World M&A volumes have shattered all-time records, with deals worthy of above $1.5 trillion inked by the world’s most significant financial commitment banking companies in the 3rd quarter, according to Refinitiv details.
Goldman comfortably held its prime rating as the world’s top lender in M&A advisory, in accordance to the Refinitiv info.
Individuals surging M&A fees drove Goldman Sachs’ all round monetary advisory profits up 225{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $1.65 billion, whilst underwriting earnings, which has been boosted by a hurry of private corporations wanting to go general public, surged 33{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $1.90 billion.
All informed, Goldman’s financial commitment lender boasted its second-very best quarter ever, with whole earnings of $3.70 billion, and executives mentioned they expect revenues to carry on to be sturdy.
“I keep on being optimistic about (possibilities),” Goldman Sachs Main Govt Officer David Solomon said on a simply call with analysts. “Activity degrees stay large especially in financial investment banking.”
Earnings for each share ended up $14.93 from $8.98 a yr earlier, outstripping the $10.18 for each share analysts had predicted, according to the IBES estimate from Refinitiv.
Goldman’s global markets investing business enterprise, which accounts for about 41{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} of total income, described earnings of $5.61 billion, up 23{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}.
The financial institution has been steadily increasing its key brokerage business enterprise, wherever it handles trades for hedge funds, choosing up clients and property as other banks have trimmed their prime divisions. Additionally, it has obtained market share when it will come to funding clients’ fairness investing, according to its quarterly report.
File picture: A perspective of the Goldman Sachs stall on the floor of the New York Inventory Exchange July 16, 2013. REUTERS/Brendan McDermid
Individuals gains in key brokerage and fairness financing assisted Goldman around double its equity trading income this quarter to $3.1 billion from $2.1a yr ago. That was larger than rival Morgan Stanley, which documented trading profits of $2.87 billion and is typically range one in this line of organization.
Morgan Stanley (MS.N) explained on Thursday that its third-quarter financial gain rose 38{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, while JPMorgan Chase & Co (JPM.N) described a 24{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} increase. browse extra Citigroup Inc. (C.N) and Financial institution of The united states Corp (BAC.N), which were likewise buoyed by deal fees and equities investing, amplified revenue by 48{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} and 64{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a}, respectively. All the banking institutions handily defeat estimates.
“Evidently, upside was anticipated given what we might seen from friends, but not this much upside,” Credit Suisse analyst Susan Roth Katzke wrote in a be aware to investors on Friday. “The conquer was broad-based mostly.”
Customer Small business
Goldman’s customer business enterprise, while tiny, has been essential to its diversification system.
As aspect of Chief Govt David Solomon’s tactic to establish alternate earnings streams, Goldman is doubling down on Marcus, its buyer lender.
Because getting around from Lloyd Blankfein in 2018, Solomon has looked to diversify revenue, with much more emphasis on shopper banking, mass-current market wealth management and hard cash management.
Internet revenue in Goldman’s client banking device rose 17{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $382 million, reflecting bigger credit history card and deposit balances.
Full financial loans increased 28{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $143 billion in the quarter from a 12 months earlier, a solid consequence in a combined quarter for personal loan expansion throughout Wall Street.
JPMorgan reported on Wednesday that loans were being up 5{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} throughout the bank in comparison with past year, whilst Citi was broadly flat. read through additional
Financial institution of America (BAC.N) and Wells Fargo (WFC.N) claimed declines in mortgage progress year-on-year.
Full earnings surged 26{1b90e59fe8a6c14b55fbbae1d9373c165823754d058ebf80beecafc6dee5063a} to $13.61 billion in the quarter, handily beating estimates.
Reporting by Noor Zainab Hussain and Anirban Sen in Bengaluru, Elizabeth Dilts and Matt Scuffham in New York Enhancing by Arun Koyyur and Nick Zieminski
/cloudfront-us-east-2.images.arcpublishing.com/reuters/E3ESHQVIJ5MA5H6DOTX4RELLIQ.jpg "Goldman Sachs cashes in on M&A wave to cap stellar quarter for U.S. banks")
